Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

While tardive dyskinesia is most often caused by sustained exposure to antipsychotics, any drug that significantly blocks dopamine receptors can be a culprit, said Demian Rose, MD, PhD, of the ...

1) Tardive syndrome (TS) is an umbrella term that can include “the spectrum of all persistent hyperkinetic, hypokinetic and sensory phenomenologies resulting from chronic dopamine receptor blocking ...

Tardive dyskinesia (TD) can cause uncontrollable jerking movements of the face, arms, or legs. It typically develops due to the use of certain medications. Tardive dyskinesia (TD) is a rare type of ...

Tardive dyskinesia is a movement disorder that causes repetitive, involuntary movements in the face, neck, arms, and legs. The condition is a side effect of certain medications. Symptoms can improve ...

Tardive dyskinesia (TD) is a movement disorder typically caused by taking neuroleptic drugs. Treatment focuses on preventing the recurrence or persistence of symptoms. Tardive dyskinesia (TD) most ...

Antipsychotics work in part by blocking dopamine receptors in your brain, but sometimes they have unintended consequences for sensory and motor function. “By definition, tardive dyskinesia is an ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...

SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase ...

NBI-98854, an experimental drug for tardive dyskinesia being developed by Neurocrine Biosciences, led to a statistically significant reduction in symptoms of the movement disorder in a phase 3, ...